INTRODUCTION
Cystic fibrosis (CF) is a lethal autosomal recessive disorder characterized by abnormal transepithelial ion transport and dehydrated mucus lining the epithelium of several organs, including the lung [1] . Within the airways, compromised innate immunity and impaired mucociliary transport facilitate chronic colonization by a variety of micro-organisms that are the major cause of patient morbidity [2, 3] . Though recent culture-independent surveys have revealed complex CF lung microbiota consisting of hundreds of bacterial species [4] [5] [6] , P. aeruginosa remains widely recognized as the primary driver of disease progression [7] . This bacterium is prevalent among 70-80% of CF adults [8] , can reach densities as high as 10 9 cells gm −1 of sputum despite aggressive antimicrobial therapies [9] , and its persistence strongly correlates with poor disease outcomes [10, 11] .
As chronic infections progress, P. aeruginosa is exposed to selective pressures that include the host immune response, competing microbiota, xenobiotics, oxidative stress and a dynamic nutritional milieu. In response, P. aeruginosa undergoes substantial genotypic and phenotypic variability. For example, loss-of-function mutations are commonly found in lasR, encoding a transcriptional regulator of quorum sensing (QS) [12] . In turn, P. aeruginosa clinical isolates exhibit altered expression of QS-regulated virulence effector molecules such as elastase, siderophores and phenazines [13] [14] [15] [16] . Additional mutations in vfr, exsA, mutS, ampR and mucA, among others, lead to mucoidy, auxotrophy, altered motility, lipopolysaccharide (LPS) modifications, hypermutability, and decreased susceptibility to phage, antimicrobials and phagocytosis [17] [18] [19] [20] [21] [22] [23] [24] . Each of these phenotypes is thought to confer a selective advantage for long-term persistence in vivo [25] .
Recently, direct measurements of CF sputum have revealed elevated concentrations (>10 µM) of agmatine, a pre-polyamine intermediate metabolite of the arginine decarboxylase pathway ( Fig. 1 ) [26] . P. aeruginosa isolates derived from CF subjects have also been found to accumulate this metabolite in vitro, though the genetic basis of this phenotype has not yet been determined [26] . Previous studies have reported elevated concentrations of the polyamines spermidine and putrescine (that are derived from agmatine) in CF sputum and bronchoalveolar lavage fluid [27, 28] . Others have demonstrated that for P. aeruginosa, polyamines contribute to increased resistance to antimicrobials and oxidative stress [29, 30] . These observations raised the question: do loss-offunction mutations leading to agmatine hyperproduction also confer an advantage to P. aeruginosa in the context of CF lung infection?
The objectives of this study were twofold. First, we sought to characterize the frequency of agmatine hyperproducers among a library of P. aeruginosa CF isolates and to determine the genetic basis of this phenotype. Next, we tested whether agmatine accumulation could protect P. aeruginosa against the host immune response and antibiotic stress. We demonstrate that agmatine confers a strain-dependent persistence advantage in the context of CF lung disease and highlight a potential new role for agmatine during P. aeruginosa infections of the lower airways.
METHODS

Bacterial strains, human epithelial cells and culture conditions
Bacterial strains and plasmids used in this study are presented in Table 1 . Strains were routinely cultured at 37 °C on LuriaBertani (LB) medium or Mueller-Hinton Broth 2 (MHB-2) as indicated. When necessary, antibiotic concentrations were added as follows: for Escherichia coli, 20 µg ml −1 tetracycline, 50 µg ml −1 ampicillin; for P. aeruginosa, 25 µg ml −1 irgasan, 25-200 µg ml −1 tetracycline, and 200 µg ml −1 carbenicillin. Clinical isolates (one per subject) were derived from stable adult outpatients at Children's Hospital Boston or the University of Minnesota. CF human bronchial epithelial cells (CF-DHBE) were acquired from Lonza and cultured using Bronchial Epithelial Cell Growth Medium (BEGM) and subculturing reagents (Lonza) according to the manufacturer's protocol. Growth medium was changed every 48 h until cells were ~80-90% confluent.
Agmatine biosensor assay
Clinical isolates were screened for agmatine accumulation using a modified bioassay described previously [31] (Fig. S1 , available in the online version of this article). Briefly, an agmatine reporter strain defective in agmatine metabolism (PA14 aguA:gm Δagu2ABCA′ ΔspeA aguRB-lux) was grown overnight in LB to stationary phase and diluted in fresh LB to a final OD 600 of ~0.2. Spent supernatants from the reporter strain were used to generate a standard curve, whereby exogenous agmatine (Sigma) was added at a concentration of 200 µM, followed by serial dilution to 0.2 µM. Then, 100 µl of each standard was added, in triplicate, to a 96-well microtitre plate. Stationary phase cultures (n=3) of P. aeruginosa clinical isolates (92 strains in total) were then centrifuged at 10 000 g for 5 min, and 100 µl of spent supernatant was added in triplicate to plates containing the standards. Finally, 100 µl of the reporter strain was added to each well, plates were covered with a Titer Top seal (Diversified Biotech) to prevent evaporation and incubated at 37 °C for 3 h. Luminescence was determined using a BioTek Synergy H1 plate reader and normalized to culture density (OD 600 ) of the reporter strain.
PCR amplification and sequencing of aguA
AccuPrime GC-Rich DNA polymerase kit (Invitrogen) and primers aguAF and aguAR (Table S1 ) were used to amplify aguA from each clinical isolate. PCR products were gel purified using QIAquick Gel Extraction kit (Qiagen) and sent to Functional Biosciences (Madison, WI) or Eurofins Genomics (Louisville, KY) for sequencing.
Plasmid construction and genetic manipulation
aguA from P. aeruginosa PA14 (WT gene) was PCR amplified and cloned into HindIII/SmaI-digested pEX18Tc using primers aguAFHindIII and aguAR forming pJLM2-WTA. To restore agmatine catabolism in MNPA04, MNPA05, MNPA06, CHB47-6 and CHB54-11, pJLM2-WTA was transformed into E. coli SM10 and mobilized into the clinical isolates. Recombinants (containing the native aguA and intact WT aguA gene from strain PA14) were selected on LB agar containing irgasan (25 µg ml −1 ) and tetracycline (25-200 µg ml −1 , depending on the isolate). Colonies were then transferred to LB agar containing 200 µg ml −1 tetracycline, grown overnight, and patched to 5 % sucrose plates. Genomic DNA from colonies that grew on sucrose was then screened by PCR and sequenced using primers aguAF and aguAR1 to confirm recombination. speA deletion mutants were generated by cloning and ligating a speA knockout construct [31] into HindIII/EcoRI-digested pEX18Tc using primer pair speAF and speAR, generating pJLM2-ΔspeA. This plasmid was then transformed into E. coli SM10 and mobilized into P. aeruginosa as described above.
Antibiotic susceptibility assay
MICs of ceftazidime hydrate (Sigma), doxycycline hyclate (Sigma), gentamicin sulfate (Amresco), tobramycin (Amresco), colistin sulfate (Santa Cruz Biotechnology) and piperacillin sodium (Gold Biotechnology) were determined using a microtitre plate-based assay. Tazobactam (10 µg ml −1 ) was also added to the piperacillin treatments. Briefly, bacterial cultures were grown overnight in LB, diluted to an OD 600 of ~0.2, and further diluted 100-fold in MHB-2. Then, 96-well plates were prepared with 100 µl of MHB-2 containing twofold dilutions of antibiotics, followed by the addition of 100 µl of diluted overnight cultures to 
Acute pneumonia mouse model
Overnight cultures of MNPA04 and MNPA04 +aguA were grown in LB, washed once in PBS, and resuspended in PBS to an OD 600 of ~1.0. Two groups (n=10) of female BALB/c mice (Jackson Laboratories), aged 8 weeks, were anesthetized using isoflurane (3% at 3 l min −1 ) and challenged intratracheally with 100 µl (1×10 8 c.f.u.) of culture using a 1 ml Hamilton syringe and a 22G×1.25' catheter (Terumo Medical). After 24 h, mice were sacrificed via CO 2 asphyxiation and cervical dislocation, followed by bronchoalveolar lavage using 2 ml of sterile PBS. Lavage fluid (BAL) was then serially diluted tenfold and plated on LB agar +irgasan to quantify P. aeruginosa load. A 100 µl aliquot of BAL was centrifuged in a Cytospin column (ThermoFisher), stained for differential white cell counts, and neutrophils were quantified using a haemocytometer. Neutrophil counts and BAL c.f.u. were compared using unpaired two-tailed t-tests with Welch's correction.
Epithelial cell culture model
CF-DHBE bronchial epithelial cells were seeded into 48-well cell culture plates (Costar) coated with bovine collagen at 5×10 4 cells per well in 250 µl of BEGM (Lonza). Cells were incubated at 37 °C in humidified air with 5% CO 2 . Media was replaced every 48 h until cells were confluent on day 10 post-seeding. Prior to treatment, cell cultures were rinsed twice with 250 µl −1 starvation medium (MEM+0.5% FBS). Cells were then stimulated by adding tenfold dilutions of agmatine (0.1-100 µM) (Sigma), 100 ng ml −1 of LPS from E. coli (Sigma), or agmatine plus LPS in starvation medium to each well. Media-only and media+LPS were used as controls. Treated cells were incubated for an additional 24 h, followed by collection of supernatants that were frozen at −80 °C for downstream analysis. Supernatants were assayed using the IL-8 Human ProcartaPlex Simplex Kit (Thermo) on the Luminex Magpix instrument according to manufacturer's protocol. Standards were run in duplicate and test samples were run in triplicate on the same plate. Cytokine concentrations were compared using a non-parametric Friedman's test with Dunn's multiple comparison post-test.
RESULTS
Agmatine accumulation among P. aeruginosa CF isolates
Given the elevated concentrations of agmatine detected within expectorated sputum and the identification of overproducing strains [26] , we first tested our hypothesis that agmatine accumulation (herein referred to as 'hyperproduction') is a common phenotype among P. aeruginosa CF isolates. To evaluate its frequency, we used a previously described biosensor assay [31] to semi-quantitatively evaluate agmatine production among a strain library comprising 92 CF airway isolates. Isolates were grown to stationary-phase, and supernatants were added to an agmatine-sensitive bioluminescent reporter derivative of P. aeruginosa PA14 [31] . Luminescence was then quantified after 3 h and normalized to culture density of the reporter strain (Fig. 2 ). Of 92 isolates tested, five (5.4%) were found to produce agmatine above the detectable threshold of ~1 µM, including three that were identified previously [26] . These concentrations were equal to or above those produced by PA14ΔaguAΔagu2Aagu2A′, an agmatine hyperproducing lab strain used in the development and validation of the assay [31] .
Since aguA encodes a deiminase that catalyses the conversion of agmatine to N-carbamoyl putrescine (Fig. 1) , we predicted that mutations at this locus were responsible for agmatine accumulation. To test this, aguA was PCR amplified from each isolate and sequenced. Interestingly, MNPA04, MNPA05 and MNPA06 each harboured an identical 11 base pair deletion in aguA (Fig. S2) , which may be indicative of patient-to-patient transmission of an agmatine-hyperproducing common ancestor. CHB47-6 and CHB54-11 also harboured 8 bp and 14 bp deletions, respectively, at the 3′ end of aguA (Fig. S2) . Each of these deletions results in a frameshift mutation in the downstream catalytic site of the deiminase. Notably, none of the five hyperproducing isolates contained the alternate agu2ABCA′ operon (encoding two additional agmatine deiminases) found in ~20 % of P. aeruginosa isolates [32] , suggesting that mutations identified in aguA were responsible for the agmatine hyperproduction phenotype. Indeed, when an intact copy of aguA was cloned from strain PA14 and mobilized via allelic exchange into the aguA mutant isolates, agmatine catabolism was restored as determined by the biosensor assay (Fig. 2) .
Agmatine hyperproduction confers increased tolerance to cationic antibiotics
The prevalence of aguA mutations among our clinical isolate library raised the question of whether agmatine hyperproduction is another example of a loss-of-function phenotype that confers a fitness advantage in vivo. Specifically, could agmatine decrease susceptibility to positively charged antibiotics that destabilize the Gram-negative outer membrane? This question was raised, in part, based on prior reports of exogenously added spermidine and putrescine conferring protection to P. aeruginosa from polymixin B [29, 35] . This was likely due to increased stability of LPS via the polycationic charge of the polyamines [29] . Though agmatine is a pre-polyamine, it also harbours a dipositive charge, and we hypothesized that its production by the aguA-clinical isolates confers a similar protective effect.
Using a microtitre plate-based assay, the MIC and IC50 (antibiotic concentration needed to halve the bacterial density at 24 h) [36] of three commonly used CF antibiotics with a polycationic charge (colistin, tobramycin and gentamicin) were determined for MNPA04 and its isogenic aguA +strain. To ensure that any observed phenotype was specific for agmatine accumulation (and not due to a defect in arginine catabolism), we also generated a MNPA04ΔspeA mutant lacking the arginine decarboxylase (SpeA) required for the first dedicated step of the pathway (see Fig. 1 ). While there was no difference in MIC for any of the compounds tested (data not shown), there was a significant increase in IC50 for each antibiotic versus the agmatine hyperproducer relative to the complemented aguA+strain (Fig. 3a, Table 2 ). This No differences in susceptibility were observed for antibiotics with a neutral or negative charge (ceftazidime, piperacillin, doxycycline). IC50 values (concentration of drug required to halve bacterial density) were determined by non-linear regression analysis using a four-parameter logistic function (see Fig. S3 ). phenotype was not observed in MNPA04ΔspeA, suggesting that the observed decreases in antibiotic susceptibility were a direct result of agmatine accumulation.
As demonstrated previously for spermidine and putrescine [29, 35] , we predicted that the dipositive charge of agmatine impeded the interaction of cationic antibiotics with the negatively charged bacterial cell surface. To test this, we treated MNPA04, MNPA04+aguA and MNPA04ΔspeA with three additional CF antibiotics that carry a net neutral or negative charge at physiological pH; ceftazidime, piperacillin and doxycycline (Fig. 3b, Table 2 ). As predicted, there were no significant changes in IC50 for the neutral or electronegative compounds, supporting the hypothesis that agmatine hyperproduction decreases P. aeruginosa susceptibility to cationic antibiotics due its dipositive charge.
Interestingly, resistance phenotypes were strain-dependent; when tobramycin, gentamicin and colistin were tested against other mutant isolates identified in our screen, agmatine conferred increased resistance in just three of five strains (Table S2) . Strain-to-strain variability was not observed for the neutral and negatively charged compounds. Notably, the two isolates for which increased resistance to the aminoglycosides (tobramycin and gentamicin) was not found also had observable phenotypes that may also contribute to antibiotic tolerance -pyomelanin hyperproduction (MNPA06) and mucoidy (CHBPA54-11) (Fig. S4) [37] [38] [39] . It is possible that these and/or other phenotypic characteristics (e.g. biofilm or aggregate formation) affect the agmatine-antibiotic interaction that was observed for MNPA04, MNPA05 and CHB47-6.
Mouse pneumonia model
Murine models have revealed both a beneficial and detrimental role of agmatine in reducing acute lung injury through modulation of inflammatory cytokines [26, 40] . However, agmatine has also been shown to reduce macrophage TNF-α and MIP-2 response to bacterial LPS [26] . This led to our hypothesis that in a murine acute pneumonia model, the airway inflammatory response to agmatine hyperproducing clinical isolates (aguA-) of P. aeruginosa would also be dampened relative to aguA+strains. To test this hypothesis, BALB/c mice were challenged intratracheally with either MNPA04 or MNPA04+aguA for 24 h, followed by quantification of neutrophil recruitment into the airways. On average, MNPA04 recruited 40% fewer neutrophils than the aguA+strain (P=0.002, Fig. 4a ). To determine whether this decrease was a result of impaired bacterial growth in vivo, P. aeruginosa c.f.u. in BAL were also quantified. Consistent with previous studies [41] , a three-log reduction in c.f.u. was observed relative to the inoculum after 24 h, yet there was no significant difference between treatment groups (P=0.48, Fig. 4 . Agmatine hyperproduction by P. aeruginosa affects neutrophil recruitment to the airways. BALB/c mice were subjected to a 24 h airway infection with either MNPA04 (aguA-) or a MNPA04+aguA strain. (a) Neutrophil counts from BAL fluids were significantly reduced (P=0.0002) when the mice were challenged with an agmatine overproducing P. aeruginosa isolate. (b) Bacterial loads were comparable between treatments, ruling out in vivo growth differences. Data shown represent individual treatments, and error bars denote mean+sem. Means were compared using an unpaired t-test using Welch's correction for variance. Fig. 4b ). These data suggest that despite a reduction of initial bacterial load, neutrophil recruitment is impaired by P. aeruginosa agmatine hyperproduction.
Epithelial cell model
Neutrophil recruitment to a site of infection is predominately mediated by the pro-inflammatory cytokine IL-8 in response to pathogen associated molecular patterns (PAMPs) [42] [43] [44] . Therefore, we speculated that the observed decrease in neutrophil recruitment in vivo was a result of P. aeruginosa-derived agmatine diminishing chemokine production. To test this, primary CF-DHBE airway epithelial cells (AECs) that were homozygous for ΔF508 in the gene encoding the CF transmembrane regulator (CFTR) protein were treated with LPS (100 ng ml −1 ) in the presence of increasing concentrations of agmatine (1-100 µM), followed by quantification of IL-8 production in the AEC culture supernatant (Fig. 5) . Relative to AECs treated with LPS treatment alone (2.8 ng ml −1 ), IL-8 levels were significantly reduced for AECs treated with LPS+100 µM agmatine (1.2 ng ml −1 ; P=0.02). IL-8 levels were also comparable to media and media+agmatine controls, suggesting that agmatine can reduce the pro-inflammatory response of AECs to bacterial infection. These data are consistent with prior studies showing a blunting of TNFα and MIP-2a in murine-derived macrophages [26] and corroborate our in vivo observations of the host response to agmatine hyperproducing clinical isolates of P. aeruginosa.
DISCUSSION
Polyamines are low molecular weight polycations ubiquitously found in all living cells. Owing to their regularly spaced positive charges, these metabolites play critical roles in cell growth and proliferation, transcription and translation, signal transduction, ion transport and other cellular processes [45, 46] . Agmatine, an important precursor to polyamine formation, is a polycationic intermediate of the arginine decarboxylase pathway for which diverse roles have also evolved. In mammals, for example, agmatine exerts its effect at multiple targets, including matrix metalloprotease and NADPH oxidase regulation, neuro-and immunomodulation, and nitric oxide synthesis [26, [47] [48] [49] . Recently, agmatine was also proposed as an environmental trigger for P. aeruginosa biofilm formation [32] , as growth of strain PA14 in the presence of exogenous agmatine showed a dose-dependent increase in biofilm development, while deletion of both aguA and agu2ABCA′ (encoding redundant agmatine deiminases that convert agmatine into N-carbamoylputrescine, Fig. 1 ) showed a significant increase in biomass relative to WT. Here we demonstrate that aguA-mutants of P. aeruginosa that hyperproduce agmatine are frequently isolated from the airways of CF patients. Moreover, we present evidence that agmatine accumulation in the extracellular milieu may confer multiple selective advantages for persistence of P. aeruginosa in vivo.
Smith et al. [15] demonstrated that during chronic airway infection, P. aeruginosa undergoes adaptive evolution through genomic variation, and that a large number of genes are targets for mutation. Mutations in the gene encoding the key quorum-sensing regulator, lasR, are especially common, and lead to defects in the production of key virulence effector compounds [12] . Loss-of-function adaptations in gacS, retS, mutS, mucA and ampR [50] [51] [52] [53] also increase in prevalence as infections progress and reflect the transition of P. aeruginosa from an acute to chronic infection phenotype. Many of these examples are mutated in only a small fraction of infections [15] , which is consistent with the prevalence of aguA mutations (~5%) among our isolate library. While this recovery rate is not nearly as high as QS-deficient (lasR), mucoid (mucA) or hypermutator (mutS) phenotypes [12, 54, 55] , parallel evolution of agmatine hyperproduction in P. aeruginosa derived from multiple patients suggests positive selection at the aguA locus. Since our isolate library was derived from de-identified sputum samples for which clinical data were not available, it is unclear whether agmatine hyperproduction is associated with the transition to chronicity. It is also not known whether aguA mutations are selected for by the in vivo microenvironment, or if aguA-environmental isolates are better poised for airway colonization. Future studies aimed at a larger patient cohort with detailed clinical data will help address these questions.
The observed decrease in susceptibility of aguA-strains to both aminoglycosides (gentamicin, tobramycin) and polymixins (colistin) suggests that the observed effect is due to a shared characteristic of the antibiotics (e.g. their positive charge). While primary cellular targets differ, the cationic nature of both drug classes is thought to increase outer membrane (OM) permeability to lysozyme and hydrophobic compounds [56, 57] . The initial action of aminoglycosides has been shown to cause disruption of salt-bridges between adjacent LPS molecules, disrupting the normal OM packing order and allowing the compound to then enter the cell and inhibit protein translation [57, 58] . Similarly, polyamines carry a polycationic charge that facilitates binding to LPS. However, owing to their small size, polyamines do not disrupt outer membrane packing or increase OM permeability on their own [58] . In fact, the polyamines spermidine and putrescine have been shown to protect Gram-negatives against antimicrobials and oxidative stress, in addition to stabilizing spheroplasts and protecting them against lysis [29, 35, 59, 60] . Given that ΔspeA mutants (defective in arginine decarboxylation) showed no resistance phenotype and that neutrally charged antibiotics were not affected by aguA mutations, we propose that agmatine also confers resistance to P. aeruginosa due to its dipositive charge.
The observed strain-to-strain variability in both agmatine overproduction and antibiotic tolerance was not unexpected, and is consistent with the notion that agmatine-mediated antibiotic inhibition can be influenced by additional factors. Alginate, for example, has been shown to restrict the diffusion of aminoglycosides (cationic), but not β-lactams (neutral), through mucoid biofilms of P. aeruginosa clinical isolates [38] . Elevated concentrations of salts increased aminoglycoside diffusion, suggesting that electrostatic interactions between cationic compounds and extracellular polymers can also impact their efficacy [38, 61] . It remains to be determined whether variations in LPS antigens or the production of the extracellular polysaccharides pel and psl that differ in charge and vary among clinical isolates, also impact susceptibility to antibiotic challenge in the presence of agmatine [62, 63] . Likewise, pyomelanin, an electronegative pigment that is overproduced due to mutations in hmgA, exhibits humic-type properties that allows for chelation of soluble cations [64] . It is possible that (in the case of MNPA06) its polyanionic charge may impact cell surface interactions with polyamines and antibiotics. We are currently using whole genome sequencing and phenotypic assays of the aguA-mutants to understand how these and other phenotypes (including biofilm formation) influence the protective effects of agmatine for P. aeruginosa.
CF airway disease is characterized by chronic, neutrophildominated inflammation in response to bacterial infection. However, P. aeruginosa can also use numerous strategies to evade detection and eradication by the immune system. These include formation of biofilms that prevent phagocytic clearance, altered expression of PAMPs such that detection by host immune receptors and downstream signalling is minimized, and direct interference with host signalling through effector molecules [65, 66] . In the case of agmatine, impaired recruitment of neutrophils is an example of the latter. More specifically, we favour the interpretation that the dipositive charge of agmatine prevents binding of LPS by LPS-binding protein (LBP) and the downstream production of pro-inflammatory cytokines (e.g. IL-8). Given that cationic antimicrobial peptides have been shown to block LPS-LBP interactions and macrophage cytokine production [67] , our data support a similar mechanism for agmatine.
It has been shown that agmatine is capable of both immune activation and inhibition depending on the presence and dose of co-stimulatory molecules [26] . This dichotomy may explain, at least in part, contrasting phenotypes (e.g. neutrophil recruitment) between the lung adapted isolate MN004 reported here, and those found for the virulent burn wound isolate PA14 [26] , which is known to produce an array of immunostimulatory exoproducts (e.g. pyocyanin). Similarily, the acute pneumonia model revealed no difference in bacterial load between aguA-and aguA+ variants of MN004, whereas an agmatine hyperproducing mutant of PA14 showed a significant in vivo growth defect relative to the wild-type [26] . These strain-to-strain variations, similar to those observed for antibiotic tolerance, underscore the potential combinatorial effect of multiple phenotypes on agmatine-mediated interactions of P. aeruginosa with its growth environment.
Despite these variations, agmatine hyperproduction may have potential consequences for long-term P. aeruginosa persistence in vivo. For example, increased tolerance to positively charged therapeutics would confer a significant growth advantage, particularly in mucus-plugged, diffusionrestricted airways with sub-inhibitory antibiotic concentrations. Further, by accumulating aguA mutations, agmatine hyperproduction would lead to an impaired ability for the host to mount an adequate reaction aimed at pathogen clearance, in turn creating an environment that facilities adaptation and chronic persistence. Further experiments using a chronic murine model of infection (to measure c.f.u. at later time points, or to measure time-to-clearance for aguA mutants versus wild-type) will be used to directly test this possibility. Either or both of these advantages, coupled with agmatine-mediated biofilm formation reported previously [32] , may represent a contributing factor to the success of aguA mutants in the CF lung environment. 
